New Drug Discovery Program Identifies Potential Treatments for Ovarian Cancer, Other Diseases

New Drug Discovery Program Identifies Potential Treatments for Ovarian Cancer, Other Diseases
Researchers have developed a new computer program, known as DrugPredict, to find new therapeutics for unmet diseases, like ovarian cancer, among medications the U.S. Food and Drug Administration (FDA) has already approved for other indications. The program predicted and researchers later confirmed that the pain medicine Indocin (indomethacin) – alone or combined with chemotherapy drugs – killed patient-derived ovarian cancer cells. Their study, "Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment," appeared in the journal Oncogene. It details DrugPredict's success in finding new disease targets for old drugs. At present, more than 70 percent of women die within five years of being diagnosed with epithelial ovarian cancer. Since developing new drugs is a long, costly process, researchers at Cleveland's Case Western Reserve University School of Medicine developed the DrugPredict program to match FDA-approved medications for new therapeutic indications. "Traditional drug discovery process takes an average of 14 years and billions of dollars of investment for a lead anti-cancer drug to make the transition from lab to clinic," the study's first author, Dr. Anil Belur Nagaraj, said in a press release. "Drug repositioning significantly shortens the long lag-phase in drug discovery and also
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *